Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AIKI~~THIS IS HUGE dividend LOAD MORE bud
AIKI .7567,with the first FDA news ,gonna fly $5.00++,better load up fast here
the history repeats here,a Spike to $3.00-5.00 on the way,got 20k shares AIKI
The hoth shares is a trap so folk can hold to their shares as he dump this! Nice move Anthony!
Time to load to get some extra HOTH shares!!! 70-1 hoth share not bad considering is trading almost at 4$
get asap here,this week will bank wowza,AIkido 13G Filing From CVI Investments Shows 5.7% Stake
check the chart,WOWZA coming April 24, 2020
1:16 pm ET
*AIkido 13G Filing From CVI Investments Shows 5.7% Stake
a run to $5.00 set up,load big am AIKI
AIKI LOAD UP,300-500%% is going SC 13G 1 a20-16796_2sc13g.htm SC 13G
CUSIP No: 008875106
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO § 240.13d-2.
(Amendment No. )*
AIkido Pharma Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
008875106
(CUSIP Number)
April 14, 2020
(Date of Event Which Requires Filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 008875106
(1)
NAMES OF REPORTING PERSONS
CVI Investments, Inc.
(2)
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
o
(b)
o
(3)
SEC USE ONLY
(4)
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
(5)
SOLE VOTING POWER
0
(6)
SHARED VOTING POWER **
2,000,000
(7)
SOLE DISPOSITIVE POWER
0
(8)
SHARED DISPOSITIVE POWER **
2,000,000
(9)
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,000,000
(10)
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
(11)
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.7%
(12)
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.
2
CUSIP No. 008875106
(1)
NAMES OF REPORTING PERSONS
Heights Capital Management, Inc.
(2)
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
o
(b)
o
(3)
SEC USE ONLY
(4)
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
(5)
SOLE VOTING POWER
0
(6)
SHARED VOTING POWER **
2,000,000
(7)
SOLE DISPOSITIVE POWER
0
(8)
SHARED DISPOSITIVE POWER **
2,000,000
(9)
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,000,000
(10)
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
(11)
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.7%
(12)
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.
3
CUSIP No: 008875106
Item 1.
(a) Name of Issuer
AIkido Pharma Inc. (the “Company”)
(b) Address of Issuer’s Principal Executive Offices
One Rockefeller Plaza, 11th Floor, New York, NY 10020
Item 2(a). Name of Person Filing
This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).
(i) CVI Investments, Inc.
(ii) Heights Capital Management, Inc.
Item 2(b). Address of Principal Business Office or, if none, Residence
The address of the principal business office of CVI Investments, Inc. is:
P.O. Box 309GT
Ugland House
South Church Street
George Town
Grand Cayman
KY1-1104
Cayman Islands
The address of the principal business office of Heights Capital Management, Inc. is:
101 California Street, Suite 3250
San Francisco, California 94111
Item 2(c). Citizenship
Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
Item 2(d) Title of Class of Securities
Common stock, $0.0001 par value per share
Item 2(e) CUSIP Number
008875106
4
CUSIP No: 008875106
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
o
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b)
o
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)
o
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)
o
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)
o
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)
o
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)
o
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)
o
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
o
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
o
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)
o
Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
The information required by Items 4(a) — (c) is set forth in Rows 5 — 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
The Company’s Prospectus Supplement (to Prospectus dated January 9, 2018, Registration No. 333-222488), filed on April 15, 2020, indicates there were 34,888,219 Shares outstanding as of the completion of the offering of the Shares referred to therein.
Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o
5
CUSIP No: 008875106
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
6
CUSIP No: 008875106
SIGNATURES
After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
Dated: April 24, 2020
CVI INVESTMENTS, INC.
HEIGHTS CAPITAL MANAGEMENT, INC.
By: Heights Capital Management, Inc.
By:
/s/ Brian Sopinsky
pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto
Name: Brian Sopinsky
Title: Secretary
By:
/s/ Brian Sopinsky
Name: Brian Sopinsky
Title: Secretary
7
CUSIP No: 008875106
EXHIBIT INDEX
EXHIBIT
DESCRIPTION
I
Limited Power of Attorney
II
Joint Filing Agreement
8
CUSIP No: 008875106
Exhibit I
LIMITED POWER OF ATTORNEY
THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called “the Company”), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.
WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked “Appendix l.”
NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.
IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.
CVI Investments, Inc.
By:
/s/ William Walmsley
William Walmsley, Director
CUSIP No: 008875106
EXHIBIT II
JOINT FILING AGREEMENT
This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of AIkido Pharma Inc., $0.0001 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Dated as of April 24, 2020
CVI INVESTMENTS, INC.
HEIGHTS CAPITAL MANAGEMENT, INC.
By: Heights Capital Management, Inc.
By:
/s/ Brian Sopinsky
pursuant to a Limited Power of Attorney
Name: Brian Sopinsky
Title: Secretary
By:
/s/ Brian Sopinsky
Name: Brian Sopinsky
Title: Secretary
can she do this shit 3 times mang?? I said can she do this a third time home run??
AIKI~~.78,,due for news,if FDA news will be 5.00++++
AIKI MA50 at .96, MA100 at $1.07,MA200 $1.46,could break all 3 with news
*AIkido 13G Filing From CVI Investments Shows 5.7% Stake
AIKI stochastic at freaking bottom reversal
AIKI .78 will run hard 300-500%% from here EASY,the the history repeats
$hoth running good news for merger. 13 g out last week for the set up
AIKI...799...bouncing off the Gap fill...looking for $ break...imo...we shall see...
Hahaha... You're funny! LOL.
You'd be surprised the tremendous influence I would on five stocks, including AIKI. These IDIOTS play around with these five without the market knowing the conspiracy going on.....I PLAY WITH THEM TOO.
It's time for AIKI to move up already!
https://www.owler.com/company/aikidopharma
There are rumors AIKI acquiring HOTH
Big deal isnt doing anything for the share price its a pos.
That would be very, very sweet!
AIKI
Oh OK, me too! Can't wait to see crazy AIKI go to above $5 again
Thanks...yeah have some from the SPEX days.
AIKI
Hi BDEZ. AIKI Waiting for that big run up.
Good luck!
Very good news thanks viewmont! Nice to see green ah.
AIKI
AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
PR Newswire PR Newswire•April 21, 2020
NEW YORK, April 21, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on April 13, 2020, the Company executed a Master License Agreement (the "License Agreement") with the University of Maryland, Baltimore ("UMB"). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.
(PRNewsfoto/AIkido Pharma Incorporated)
More
The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson. The Company has also executed a Sponsored Research Agreement with UMB to support the development of the technology.
Mr. Anthony Hayes, CEO of AIkido, stated, "We are excited to move forward with this new antiviral platform. The pedigree of the inventors and the institution is first rate. We believe the doctors and UMB are both leaders in the field and are frequently cited in major publications discussing viruses generally, as well as COVID-19. We are proud to partner with them in this critical undertaking."
Hayes continued, "We have also added significant depth to our board of directors. Our recent capital raise has positioned the Company to comfortably fund current operations and acquire new assets. Management believes that our new board members bring significant capital market and M&A experience, which we plan to leverage. While the world works to overcome the difficult challenges as a result of the pandemic, we at AIkido are excited to look to the future."
Anytime I pull up this AIKI stock and watch the DUMB MMs , I get reminded of my thing. When it's up, you'd think it will take down an entire city. But, a few minutes later, its limp like a dead snake. No better comparison between it and AIKI Market Makers!!!
Traded some premkt and have bought all back from DUMB MMs. $378 Profits locked. AIKI Market makers are IDIOTS
Needs to break $1 to get traction again
Forget the HOTH already, it's just a teaser.
There are many here like myself who are tired of pinball AIKI common. We would appreciate the opportunity to convert our bags of common to AIKI Preferred at a discount; a one time gift to Longs.They could restrict them 6 months I don't really care. That said, I have a suspicion they know what they are doing.
I looked in the 8K and I hope that's a typo about the 1 for 500. Dwilli_2 was right, that's what it says in the 8K.
In the past they made typos and changes as you recall, first it was 1-70, then it was 1-170, then they changed back to 1-70. Now 8K says 1-500? Something's not right with this picture, hopefully a typo or a mistake.
https://app.quotemedia.com/data/downloadFiling?webmasterId=102213&ref=114947583&type=HTML&symbol=AIKI&companyName=AIkido+Pharma+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2020-04-20&CK=12239
https://ir.aikidopharma.com/sec-filings/
Yes that's / you're correct. We'll receive 1 share of HOTH for every 70 shares of AIKI owned.
https://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-change-in-the-record-date-and-anticipated-distribution-date-for-dividend-distribution-301023098.html
Today an announcement popped in TOS that AIKI sets April 30 record date for HOTH distribution.
AIkido Pharma Inc. Sets Record Date for Hoth Distribution
NEW YORK, April 20, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") is April 30, 2020, and the Company is currently working to determine the date of distribution.
https://www.prnewswire.com/news-releases/aikido-pharma-inc-sets-record-date-for-hoth-distribution-301043157.html
Remember this March 13 PR to Shareholders
Dividend distribution of one HOTH for 70 AIKI share batches, not 500 share batches. "Facts are stubborn things".
NEW YORK, March 13, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), formerly known as Spherix Incorporated, today announced that the record date and distribution date have changed for the previously announced distribution to AIkido stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by AIkido.
Each AIkido stockholder will be entitled to receive one (1) share of Hoth common stock for every seventy (70) shares of AIkido common stock held as of 5 p.m. Eastern Time on March 16, 2020, the new record date. The distribution date of the dividend distribution is anticipated to occur on or around April 30, 2020; however, this date is subject to change based upon the filing date of a registration statement by Hoth.
Classic PR misinformation. Just saying.
It says 1 for 500 in the 8k.....
Ironically, today's PR doesn't actually reaffirm
the HOTH to AIKI ratio for dividend distribution. Hope it's still 1-70 and not some bait and switch. GLTA
Unfortunately we're still stuck with the scumbag.
Especially for a band of MARKET MAKERS (AIKI MMs) that I have not credited with any intelligence other than that accustomed with a first grader!!!
Frankly baffled at the new smartness. I guess after several losses following me around, gapping holes in their pockets teach them some manners. Still waiting....
Strange that the DUMB, CLUELESS MARKET MAKERS here are not taking my bait to sell lower....who gave these fools some brain?????
I kept waiting for them to return the stock to $0.60, but IDIOTS just commit fraud by fake-selling to themselves. 1934 Act...still in vogue!!!
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |